Opportunity Information: Apply for PA 18 791
Apply for PA 18 791
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865.
- This funding opportunity was created on 2018-05-21.
- Applicants must submit their applications by 2021-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) funding opportunity titled "Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)" (Funding Opportunity Number: PA-18-791; CFDA: 93.865) supports small, focused research projects that aim to improve patient safety for newborns and young children, with particular emphasis on perinatal and neonatal care. It is designed to encourage collaborative work that can generate practical knowledge about how and why medical errors occur in both routine newborn care and high-acuity settings such as neonatal intensive care units, and what can be done at multiple levels to prevent those errors and reduce harm. Because this is an R03 mechanism, it generally aligns with pilot or feasibility-style projects that can produce early evidence, refined methods, preliminary datasets, or proof-of-concept findings that help move a safety idea toward broader testing and adoption.
The scope of research is intentionally broad and includes, but is not limited to, studies that describe the epidemiology of medical errors and related patient harm in perinatal, neonatal, and pediatric settings. That can include work that measures how often certain errors occur, what types of harms result, which populations are most affected, and how patterns differ across clinical environments, staffing models, or care processes. The FOA also emphasizes research that identifies and evaluates contributing factors at different levels, such as individual clinician decision-making, communication and teamwork, workflow and handoffs, technology and documentation, organizational policies, and institutional culture. In addition to understanding the problem, the announcement invites intervention-oriented research that tests strategies to reduce or eliminate errors. These interventions may target individuals (for example, training, decision support, or checklists), systems (such as standardized protocols, redesigned care pathways, or improved handoff structures), or institutions (like safety culture initiatives, reporting systems, or policy changes). Overall, the goal is to build evidence that can translate into safer, higher-quality care for all newborn infants, emphasizing both safety and effectiveness.
Clinical trials are optional under this announcement, meaning applicants can propose either observational and analytic studies or interventional studies, as long as the work fits NIH definitions and requirements for the chosen approach. This flexibility allows projects ranging from chart review and safety surveillance, to qualitative investigations of contributing factors, to pilot testing of a safety intervention in a clinical unit. The announcement frames the expected impact in practical terms: the knowledge gained should help health systems develop and refine strategies that reliably deliver the highest quality of care with the least preventable harm during the perinatal and neonatal period, including intensive care contexts.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations (other than federally recognized tribal governments); public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education when specified in the listing); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. At the same time, the announcement clearly restricts foreign participation: non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed.
From a practical standpoint, the award information provided indicates an award ceiling of $50,000, consistent with small grant expectations under an R03. The original closing date listed is 2021-09-07, and the opportunity was created on 2018-05-21, which is important for applicants to verify current availability or any reissued/replaced versions of the FOA before planning a submission. The program sits within NIH's health research portfolio and targets actionable research that can identify where safety breaks down in perinatal, neonatal, and pediatric care and demonstrate feasible, scalable approaches to preventing medical errors and protecting infants and children from avoidable harm.
FAQs: NIH Grant - Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)
What is the title of this NIH funding opportunity?
The funding opportunity is titled "Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)."
What is the Funding Opportunity Number (FON) for this program?
The Funding Opportunity Number is PA-18-791.
What CFDA number is associated with this opportunity?
The CFDA number listed is 93.865.
What is the main purpose of this grant opportunity?
This NIH opportunity supports small, focused research projects aimed at improving patient safety for newborns and young children, with particular emphasis on perinatal and neonatal care. It encourages collaborative research that produces practical knowledge about how and why medical errors occur in routine newborn care and high-acuity settings (such as neonatal intensive care units), and what can be done to prevent errors and reduce harm at multiple levels.
What does the R03 mechanism imply about project size and scope?
Because this is an R03 mechanism, it generally aligns with pilot or feasibility-style projects. The expectation is that projects will produce early evidence, refined methods, preliminary datasets, or proof-of-concept findings that help move a patient safety idea toward broader testing and adoption.
Which patient populations and care settings are emphasized?
The focus is on newborns and young children, emphasizing the perinatal and neonatal period. The scope includes both routine care settings and high-acuity environments such as neonatal intensive care units.
What types of research topics are within scope?
The scope is intentionally broad. It includes (but is not limited to) studies that (1) describe the epidemiology of medical errors and related harm in perinatal, neonatal, and pediatric settings, (2) identify and evaluate contributing factors across multiple levels (individual, team/workflow, technology/documentation, organizational policies, and culture), and (3) test interventions designed to reduce or eliminate errors.
What does "epidemiology of medical errors and related patient harm" mean in this context?
Within this FOA, epidemiology-oriented work can include measuring how often certain errors occur, what kinds of harms result, which populations are most affected, and how patterns differ across clinical environments, staffing models, or care processes.
What kinds of contributing factors does NIH want applicants to study?
The FOA highlights contributing factors at multiple levels, including individual clinician decision-making, communication and teamwork, workflow and handoffs, technology and documentation, organizational policies, and institutional culture.
Are intervention studies allowed, or is the FOA limited to observational research?
Intervention-oriented research is explicitly invited. Applicants may propose strategies to reduce or eliminate errors, including interventions targeting individuals, systems, or institutions, as long as the work fits the FOA and relevant NIH definitions and requirements.
What are examples of individual-level interventions mentioned in the announcement?
Examples include training, decision support, or checklists.
What are examples of system-level interventions mentioned in the announcement?
Examples include standardized protocols, redesigned care pathways, or improved handoff structures.
What are examples of institution-level interventions mentioned in the announcement?
Examples include safety culture initiatives, reporting systems, or policy changes.
Are clinical trials required under this FOA?
No. Clinical trials are optional under this announcement, meaning applicants may propose either observational/analytic studies or interventional studies, depending on what best fits their aims.
What does "Clinical Trial Optional" practically allow an applicant to propose?
It allows a wide range of project types, including chart review and safety surveillance, qualitative investigations of contributing factors, and pilot testing of a safety intervention in a clinical unit, as long as the chosen approach aligns with NIH definitions and requirements for that study type.
What kind of impact is NIH expecting from funded projects?
The FOA frames impact in practical terms: the knowledge gained should help health systems develop and refine strategies that reliably deliver the highest quality care with the least preventable harm during the perinatal and neonatal period, including intensive care contexts. The overall goal is safer, higher-quality care for newborn infants, emphasizing both safety and effectiveness.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and governmental entities. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations (other than federally recognized tribal governments); public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education when specified in the listing); for-profit organizations other than small businesses; and small businesses.
Does the FOA highlight any specific institution types as eligible?
Yes. The FOA explicitly highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Are non-U.S. (foreign) organizations eligible to apply?
No. The announcement restricts foreign participation. Non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply.
Can a U.S. organization include a non-domestic component on the application?
No. The FOA states that non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy definitions?
No. The FOA indicates that foreign components, as defined by the NIH Grants Policy Statement, are not allowed.
What is the award ceiling indicated for this R03 opportunity?
The award information provided indicates an award ceiling of $50,000, consistent with small grant expectations under an R03 mechanism.
When was this opportunity created?
The opportunity was created on 2018-05-21.
What is the closing date listed for this opportunity?
The original closing date listed is 2021-09-07.
What should applicants do given the listed closing date?
Because the closing date listed is 2021-09-07, applicants should verify current availability and check whether the FOA has been reissued, replaced, or updated before planning a submission.
What broader NIH research area does this program fall under?
This opportunity sits within NIH's health research portfolio and targets actionable research to identify where safety breaks down in perinatal, neonatal, and pediatric care and to demonstrate feasible, scalable approaches to preventing medical errors and protecting infants and children from avoidable harm.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
Previous opportunity: International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 18 791
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 18 791) also looked into and applied for these:
| Funding Opportunity |
|---|
| Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed) Apply for RFA MH 19 201 Funding Number: RFA MH 19 201 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (U01 Clinical Trial Not Allowed) Apply for RFA MH 19 200 Funding Number: RFA MH 19 200 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Immune Mechanisms at the Maternal-Fetal Interface (R01 Clinical Trial Optional) Apply for RFA AI 18 023 Funding Number: RFA AI 18 023 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed) Apply for PAR 18 831 Funding Number: PAR 18 831 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed) Apply for RFA HD 19 015 Funding Number: RFA HD 19 015 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $500,000 |
| Enhancing Developmental Biology Research at Academic Research Enhancement Award Eligible Institutions (R15 - Clinical Trial Not Allowed) Apply for PAR 18 834 Funding Number: PAR 18 834 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 - Clinical Trial Optional) Apply for PA 18 838 Funding Number: PA 18 838 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional) Apply for PA 18 839 Funding Number: PA 18 839 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Pediatric Critical Care and Trauma Scientist Development Program (K12 Clinical Trial Optional) Apply for RFA HD 19 008 Funding Number: RFA HD 19 008 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $600,000 |
| Novel Approaches to Safe, Non-Invasive, Real Time Assessment of Human Placenta Development and Function Across Pregnancy (R21 - Clinical Trial Not Allowed) Apply for PAR 18 885 Funding Number: PAR 18 885 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Novel Approaches to Safe, Non-Invasive, Real Time Assessment of Human Placenta Development and Function Across Pregnancy (R01 - Clinical Trial Not Allowed) Apply for PAR 18 884 Funding Number: PAR 18 884 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) Apply for PAR 18 953 Funding Number: PAR 18 953 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) Apply for PAR 18 952 Funding Number: PAR 18 952 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Reproductive Medicine Collaborative Clinical Trials Program (Collaborative R01 Clinical Trial Required) Apply for RFA HD 19 022 Funding Number: RFA HD 19 022 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed) Apply for RFA HD 19 025 Funding Number: RFA HD 19 025 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Contraception Research Centers Program (U54 Clinical Trial Optional) Apply for RFA HD 19 023 Funding Number: RFA HD 19 023 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Womens HIV Epidemiology Cohort Studies (R01 Clinical Trial Not Allowed) Apply for RFA HD 19 024 Funding Number: RFA HD 19 024 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $250,000 |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center (UM1 Clinical Trial Required) Apply for RFA AI 19 006 Funding Number: RFA AI 19 006 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network Leadership and Operations Center (UM1 Clinical Trial Required) Apply for RFA AI 19 004 Funding Number: RFA AI 19 004 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed) Apply for RFA NS 19 022 Funding Number: RFA NS 19 022 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $2,250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 18 791", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.